Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gurdeep Chhabra

Hematology & Oncology California, MD Medical Doctor

NPI 1336173277 CMS profile 196484

23415 Three Notch Rd Ste 2050, California, MD 20619

Open in the dashboard

General payments

$51,583

620 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gurdeep Chhabra of California, MD is reported in the CMS Open Payments database as having received $51,583 across 620 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,342 103
2024 General $2,317 78
2023 General $6,945 105
2022 General $2,285 88
2021 General $11,073 81
2020 General $3,777 64
2019 General $20,843 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gurdeep Chhabra
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Gurdeep Chhabra were reported at $4,342. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Gurdeep Chhabra Hematology & Oncology median Middle half National median
2019 $20,843 $529 $121–$2,516 $163
2020 $3,777 $339 $82–$2,213 $114
2021 $11,073 $263 $49–$1,965 $132
2022 $2,285 $416 $103–$2,395 $149
2023 $6,945 $542 $125–$2,646 $160
2024 $2,317 $692 $141–$3,008 $164
2025 $4,342 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $12,849 71 payments
  2. Pfizer Inc. $10,733 54 payments
  3. Celgene Corporation $8,406 23 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $4,716 15 payments
  5. AstraZeneca Pharmaceuticals LP $2,631 35 payments
  6. Janssen Biotech, Inc. $1,316 54 payments
  7. Puma Biotechnology, Inc. $1,295 15 payments
  8. Janssen Global Services, LLC $883 2 payments
  9. Merck Sharp & Dohme Corporation $724 38 payments
  10. Incyte Corporation $623 19 payments
  11. Other $7,408 294 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $15,544 7 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,385 7 payments
  3. Food and Beverage $13,309 570 payments
  4. Honoraria $3,830 3 payments
  5. Travel and Lodging $2,247 6 payments
  6. Long term medical supply or device loan $1,631 18 payments
  7. Education $638 9 payments
Products named General payments · program years 2019–2025
  1. KISQALI $10,082 41 payments
  2. PIQRAY $9,789 11 payments
  3. Revlimid $8,073 6 payments
  4. IBRANCE $6,195 18 payments
  5. Nubeqa $4,693 14 payments
  6. LYNPARZA $2,109 10 payments
  7. LORBRENA $1,806 9 payments
  8. NERLYNX $1,184 10 payments
  9. KEYTRUDA $595 32 payments
  10. OPDIVO $537 18 payments
  11. Other $14,049 619 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,159

Median for Hematology-Oncology: 604

Drug cost

$2,380,674

Median for Hematology-Oncology: $1,306,514

Branded share of claims

27.7%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 60 $791,228
Revlimid Lenalidomide Brand 24 $426,723
Tagrisso Osimertinib Mesylate Brand 17 $320,344
Imbruvica Ibrutinib Brand 19 $314,236
Lenalidomide Generic 21 $206,097
Abiraterone Acetate Generic 25 $136,575
Eliquis Apixaban Brand 130 $116,980
Imatinib Mesylate Generic 11 $31,212
Prolia Denosumab Brand 13 $22,016
Letrozole Generic 193 $4,805

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 131 billing codes

Paid by Medicare

$2,576,062

Of which drugs: $2,176,081

Medicare patients

692

Average age 75

Services billed

189,141

436 women, 256 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 58%
Arthritis 48%
Diabetes 45%
Chronic kidney disease 37%
Ischemic heart disease 34%
COPD 21%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 14 5,280 $109,452
Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg Q5108 Office 11 444 $49,440
Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 Office 19 6,601 $42,998
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg J2506 Office 16 780 $38,828
Injection, epoetin alfa, biosimilar, (retacrit) (for non-esrd use), 1000 units Q5106 Office 15 2,680 $15,467
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 Office 27 30,090 $8,248
Injection, docetaxel, 1 mg J9171 Office 11 4,421 $2,969
Injection, iron sucrose, 1 mg J1756 Office 15 10,000 $1,739
Injection, palonosetron hcl, 25 mcg J2469 Office 40 2,210 $1,569
Injection, carboplatin, 50 mg J9045 Office 12 319 $914

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 57 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $253
  • PFIZER INC. $7
$260 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $220
$220 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $70
$70 — —
IMBRUVICA
  • AbbVie, Inc. $62
$62 19 —
SARCLISA
  • GENZYME CORPORATION $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 57 with Patron

Records

620 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record